COX-2 inhibition and colorectal cancer

Claus Henning Koehne, Raymond N. Dubois

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Mortality in patients with advanced colorectal cancer (CRC) remains high. Epidemiologic studies show that individuals taking nonselective, nonsteroidal anti-inflammatory drugs, including aspirin, have a significant reduction in CRC mortality, compared with those not taking these agents. The recent characterization of cyclooxygenase-1 and -2 (COX-1 and COX-2) isoforms has led to an expanded understanding of how nonsteroidal anti-inflammatory drugs may help prevent polyp formation. Cyclooxygenase enzymes are required for the conversion of arachidonic acid to prostaglandins. COX-2 mediates the inflammatory effects of COX activity, is induced by a wide spectrum of growth factors and proinflammatory cytokines, and is overexpressed in numerous premalignant and malignant lesions, including CRC. Treatment with the selective COX-2 inhibitor celecoxib has shown promising results in the prevention of CRC. Numerous studies show that this COX-2 selective inhibitor is a potent suppressor of colon polyps both in animal models for familial adenomatous polyposis and in patients with this condition. This has led to the US Food and Drug Administration approval of celecoxib for the treatment of patients with familial adenomatous polyposis. The role of celecoxib in cancer treatment is still evolving. Recent studies have identified a potential benefit for adding celecoxib to standard CRC chemotherapy regimens to increase their efficacy and reduce their associated toxicity.

Original languageEnglish (US)
Pages (from-to)12-21
Number of pages10
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 7
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Celecoxib
Colorectal Neoplasms
Adenomatous Polyposis Coli
Cyclooxygenase 2 Inhibitors
Polyps
Anti-Inflammatory Agents
Drug Approval
Cyclooxygenase 1
Mortality
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Arachidonic Acid
Pharmaceutical Preparations
Aspirin
Prostaglandins
Epidemiologic Studies
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Colon
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

COX-2 inhibition and colorectal cancer. / Koehne, Claus Henning; Dubois, Raymond N.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 7, 04.2004, p. 12-21.

Research output: Contribution to journalArticle

Koehne, Claus Henning ; Dubois, Raymond N. / COX-2 inhibition and colorectal cancer. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 7. pp. 12-21.
@article{1081a14e06f5468f8c64fbdd12a39c11,
title = "COX-2 inhibition and colorectal cancer",
abstract = "Mortality in patients with advanced colorectal cancer (CRC) remains high. Epidemiologic studies show that individuals taking nonselective, nonsteroidal anti-inflammatory drugs, including aspirin, have a significant reduction in CRC mortality, compared with those not taking these agents. The recent characterization of cyclooxygenase-1 and -2 (COX-1 and COX-2) isoforms has led to an expanded understanding of how nonsteroidal anti-inflammatory drugs may help prevent polyp formation. Cyclooxygenase enzymes are required for the conversion of arachidonic acid to prostaglandins. COX-2 mediates the inflammatory effects of COX activity, is induced by a wide spectrum of growth factors and proinflammatory cytokines, and is overexpressed in numerous premalignant and malignant lesions, including CRC. Treatment with the selective COX-2 inhibitor celecoxib has shown promising results in the prevention of CRC. Numerous studies show that this COX-2 selective inhibitor is a potent suppressor of colon polyps both in animal models for familial adenomatous polyposis and in patients with this condition. This has led to the US Food and Drug Administration approval of celecoxib for the treatment of patients with familial adenomatous polyposis. The role of celecoxib in cancer treatment is still evolving. Recent studies have identified a potential benefit for adding celecoxib to standard CRC chemotherapy regimens to increase their efficacy and reduce their associated toxicity.",
author = "Koehne, {Claus Henning} and Dubois, {Raymond N.}",
year = "2004",
month = "4",
doi = "10.1016/j.seminoncol.2004.03.041",
language = "English (US)",
volume = "31",
pages = "12--21",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 7",

}

TY - JOUR

T1 - COX-2 inhibition and colorectal cancer

AU - Koehne, Claus Henning

AU - Dubois, Raymond N.

PY - 2004/4

Y1 - 2004/4

N2 - Mortality in patients with advanced colorectal cancer (CRC) remains high. Epidemiologic studies show that individuals taking nonselective, nonsteroidal anti-inflammatory drugs, including aspirin, have a significant reduction in CRC mortality, compared with those not taking these agents. The recent characterization of cyclooxygenase-1 and -2 (COX-1 and COX-2) isoforms has led to an expanded understanding of how nonsteroidal anti-inflammatory drugs may help prevent polyp formation. Cyclooxygenase enzymes are required for the conversion of arachidonic acid to prostaglandins. COX-2 mediates the inflammatory effects of COX activity, is induced by a wide spectrum of growth factors and proinflammatory cytokines, and is overexpressed in numerous premalignant and malignant lesions, including CRC. Treatment with the selective COX-2 inhibitor celecoxib has shown promising results in the prevention of CRC. Numerous studies show that this COX-2 selective inhibitor is a potent suppressor of colon polyps both in animal models for familial adenomatous polyposis and in patients with this condition. This has led to the US Food and Drug Administration approval of celecoxib for the treatment of patients with familial adenomatous polyposis. The role of celecoxib in cancer treatment is still evolving. Recent studies have identified a potential benefit for adding celecoxib to standard CRC chemotherapy regimens to increase their efficacy and reduce their associated toxicity.

AB - Mortality in patients with advanced colorectal cancer (CRC) remains high. Epidemiologic studies show that individuals taking nonselective, nonsteroidal anti-inflammatory drugs, including aspirin, have a significant reduction in CRC mortality, compared with those not taking these agents. The recent characterization of cyclooxygenase-1 and -2 (COX-1 and COX-2) isoforms has led to an expanded understanding of how nonsteroidal anti-inflammatory drugs may help prevent polyp formation. Cyclooxygenase enzymes are required for the conversion of arachidonic acid to prostaglandins. COX-2 mediates the inflammatory effects of COX activity, is induced by a wide spectrum of growth factors and proinflammatory cytokines, and is overexpressed in numerous premalignant and malignant lesions, including CRC. Treatment with the selective COX-2 inhibitor celecoxib has shown promising results in the prevention of CRC. Numerous studies show that this COX-2 selective inhibitor is a potent suppressor of colon polyps both in animal models for familial adenomatous polyposis and in patients with this condition. This has led to the US Food and Drug Administration approval of celecoxib for the treatment of patients with familial adenomatous polyposis. The role of celecoxib in cancer treatment is still evolving. Recent studies have identified a potential benefit for adding celecoxib to standard CRC chemotherapy regimens to increase their efficacy and reduce their associated toxicity.

UR - http://www.scopus.com/inward/record.url?scp=3042788940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042788940&partnerID=8YFLogxK

U2 - 10.1016/j.seminoncol.2004.03.041

DO - 10.1016/j.seminoncol.2004.03.041

M3 - Article

VL - 31

SP - 12

EP - 21

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 7

ER -